Frequently Asked Questions
The market is segmented based on , By Diagnosis (Blood Test, Urine Test, DNA Test, and Serum Test), Treatment (Gonadotropin-Releasing Hormone Analogues and Prophylactic Hematin Infusions), End Users (Hospitals, Clinics, and Research Centers) – Industry Trends and Forecast to 2031.
.
The Global Acute Intermittent Porphyria Market size was valued at USD 4.35 USD Billion in 2023.
The Global Acute Intermittent Porphyria Market is projected to grow at a CAGR of 5.9% during the forecast period of 2024 to 2031.
The major players operating in the market include Siemens AG (Germany), Sonova Holding AG (Switzerland), C. R. Bard, Inc. (U.S.), Boston Scientific Corporation (U.S.), Koninklijke Philips N.V. (Netherlands), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), ARKRAY, Inc. (Japan), ACON Laboratories, Inc. (U.S.), Nurotron Biotechnology Co. Ltd. (China).
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
